Clinical trials in Alzheimer disease: Debate on the use of placebo controls

Alzheimer Disease and Associated Disorders

Volumn 13, Issue 3, 1999, Pages 124-129

  Kawas, Claudia H ^a   Clark, Christopher M ^b   Farlow, Martin R ^c   Knopman, David S ^d   Marson, Daniel ^e   Morris, John C ^f   Thal, Leon J ^g   Whitehouse, Peter J ^h  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e The University of Alabama at Birmingham   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTICOAGULANT AGENT; CHOLINESTERASE INHIBITOR; DIHYDROERGOTOXINE MESILATE; DONEPEZIL; HERBACEOUS AGENT; PLACEBO; SELEGILINE; TACRINE;

ALZHEIMER DISEASE; DRUG EFFICACY; EDITORIAL; HUMAN; INFORMED CONSENT; MEDICAL ETHICS; METHODOLOGY; PRIORITY JOURNAL;

EID: 0032730368     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-199907000-00002     Document Type: Editorial

References (28)

1. American Psychiatric Association. Practice guidelines for major depressive disorder in adults. Am J Psychiatry 1993;150(suppl 14):1-26.
2. Cassel C, and Alzheimer's Association Ethics Advisory Panel. Are placebo-controlled trials ethical when testing Alzheimer drugs? Summary recommendations to the National Alzheimer's Association Board, May 16, 1998.
3. Chalmers TC, Matta RJ, Smith H Jr, Kunzler AM. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med 1977;297:1091 -6.
4. Chatellier G, Lacomblez L. Tacrine (tetrahydroaminoacridine: THA) and lecithin in senile dementia of the Alzheimer type: a multicenter trial. Br Med J 1990;300:495-99.
5. Corey-Bloom J, Anad R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharm 1998;1:55-65.
6. Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease: the Tacrine Collaborative Study Group. N Engl J Med 1992;327:1253-9.
7. Doraiswamy PM, Steffens DC. Combination therapy for early Alzheimer's disease: what are we waiting for? J Am Geriatr Soc 1998;46:1322-24.
8. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;268:2523-9.
9. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
10. Gauthier S, Bouchard R, Lamontagne A, et al. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. N Engl J Med 1990;322:1272-76.
11. Graves AB, Kukull WA. The epidemiology of dementia. In: Morris JC, ed. Handbook of dementing illnesses. New York: Marcel Dekker, 1994:23-69.
12. Growdon J. Biologic therapies for Alzheimer's disease. In: Whitehouse P, ed. Dementia. Philadelphia: Davis, 1993:375-99.
13. Karlawish JHT, Whitehouse PJ. Is the placebo control obsolete in a world after donepezil and vitamine E? Arch Neurol 1998;55:1420-24.
14. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-91.
15. Knopman D, Kahn J, Miles S. Clinical research designs for emerging treatments for Alzheimer disease. Moving beyond placebo-controlled trials. Arch Neurol 1998;55:1425-29.
16. Knopman DS, Morris JC. An update on primary drug therapies for Alzheimer disease. Arch Neurol 1997;54:1406-9.
17. Marson DC, Ingram KK, Cody HA, Harrell LE. Assessing the competency of patients with Alzheimer's disease under different legal standards. Arch Neurol 1995;52:949-54.
18. Marson DC, McInturff B, Hawkins L, Bartolucci A, Harrell LE. Consistency of physician judgments of capacity to consent in mild Alzheimer's disease. J Am Geriatr Soc 1997;45:453-57.
19. Morris JC. Conflicts of interest: research and clinical care [review]. Alzheimer Dis Assoc Disord 1994;8(suppl 4):49-57.
20. Morris J, Cyrus P, Orazem J, et al. Metrifonate: potential therapy for Alzheimer's disease. Neurology 1997;48:1730.
21. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998;50:1222-30.
22. Muncie HL Jr, Magaziner J, Hebel JR, Warren JW. Proxies' decisions about clinical research participation for their charges. J Am Geriatr Soc 1997;45:929-33.
23. Post SG, Whitehouse PJ. Emerging antidementia drugs: a preliminary ethical view. J Am Geriatr Soc 1998;46:784-7.
24. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-45.
25. Rothman KJ, Michels KB. Sounding board: the continuing unethical use of placebo controls. N Engl J Med 1994;331:394-7.
26. Sano M, Ernesto C, Thomas RG, et al. A controlled clinical trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997;336:1216-22.
27. Thal LJ, Schwartz G, Sano M, et al. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Neurology 1996;47:1389-95.
28. Wilcock G, Wilkinson D. Galanthamine hydrobromide: interim results of a group comparative, placebo controlled study of efficacy and safety in patients with a diagnosis of senile dementia of the Alzheimer type. Neurobiol Aging 1996;17(Suppl 43):S144.